Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, 1225 Center Drive, Gainesville, FL 32610, USA; Center for Drug Evaluation and Safety, College of Pharmacy, 1225 Center Drive, Gainesville, FL 32610, USA.
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, 1225 Center Drive, Gainesville, FL 32610, USA.
Drug Alcohol Depend. 2019 Nov 1;204:107600. doi: 10.1016/j.drugalcdep.2019.107600. Epub 2019 Sep 27.
With increasing efforts to scrutinize and reduce opioid prescribing, limited data exist on the recent trend in receipt of prescription pain medications before diagnosis of opioid use disorder (OUD) or opioid-related overdose (OD).
Using 2005-2016 Truven MarketScan Commercial Claims databases, we assessed trends in annual 1) incidence of OUD or OD and 2) prevalence of receipt of prescription opioids or four commonly-prescribed adjuvant analgesics among patients newly diagnosed with OUD/OD. Trends were examined in the overall sample and by 3 age groups, including youths (≤18 years), adults (19-64 years), and older adults (≥65 years).
The incidence of diagnosed OUD or OD increased more than 3-fold from 4.99 to 23.81 per 10,000 persons from 2006 to 2016, with the highest increase (14.18-fold) seen in older adults, followed by adults (3.53-fold), and youths (0.16-fold). Between 2006 and 2016, the proportion of patients with incident OUD/OD who received anticonvulsant adjuvant analgesics in the year before diagnosis increased (from 23.4% to 34.3% [P-trend = .005]) whereas the proportion receiving high-dose prescriptions opioids decreased (from 45.5% to 34.8% [P-trend =< .001]). A decreasing trend was observed in general for tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors.
In US commercially insured patients newly diagnosed with OUD/OD, receipt of high-dose opioid prescriptions preceding the diagnosis decreased over time, paralleled by increased use of anticonvulsants commonly prescribed for pain conditions. Further investigations are warranted to understand how prescribed and anticonvulsants contribute to the development of OUD/OD.
随着对阿片类药物处方进行审查和减少的努力不断增加,关于在诊断阿片类药物使用障碍(OUD)或与阿片类药物相关的过量用药(OD)之前接受处方止痛药物的最新趋势的数据有限。
使用 2005-2016 年 Truven MarketScan 商业索赔数据库,我们评估了以下两个方面的年度趋势:1)新诊断为 OUD/OD 的患者中 OUD 或 OD 的发病率;2)新诊断为 OUD/OD 的患者中接受处方类阿片药物或四种常用辅助镇痛药的患病率。在总体样本和 3 个年龄组(包括青少年(≤18 岁)、成年人(19-64 岁)和老年人(≥65 岁))中检查了趋势。
从 2006 年到 2016 年,诊断为 OUD 或 OD 的人数增加了 3 倍以上,从每 10000 人 4.99 例增加到 23.81 例,老年人的增幅最高(14.18 倍),其次是成年人(3.53 倍)和青少年(0.16 倍)。2006 年至 2016 年间,新诊断为 OUD/OD 的患者中有更多患者在诊断前一年接受了抗惊厥辅助镇痛药(从 23.4%增加到 34.3%[P 趋势=.005]),而接受高剂量阿片类药物处方的患者比例下降(从 45.5%下降到 34.8%[P 趋势<.001])。三环类抗抑郁药和 5-羟色胺和去甲肾上腺素再摄取抑制剂的总体呈下降趋势。
在接受商业保险的美国新诊断为 OUD/OD 的患者中,高剂量阿片类药物处方的使用在诊断前随时间减少,同时常用于治疗疼痛的抗惊厥药的使用增加。需要进一步调查以了解处方和抗惊厥药如何导致 OUD/OD 的发展。